Biotech Analyst Peaker, along with Dr. Modi, Asst Professor of Surgery at Chicago Medical School, provide an overview of Upper Track Urothelial Cancer (UTUC), commerical and growth potential for UroGen Pharma’s UGN-102 and Jelmyto on an Analyst/Industry conference call to be held on August 16 at 3 pm. Webcast Link
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on URGN:
- TD Cowen biotech analyst to hold an analyst/industry conference call
- UroGen Pharma sees FY23 JELMYTO revenue $76M-$86M
- UroGen Pharma reports Q2 EPS ($1.03) vs. ($1.18) last year
- URGN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- ‘Opportunities Outweigh Risks’: Oppenheimer Sees at Least 60% Gains in These 2 Stocks
